Real-World Comparative Effectiveness and Safety of BTK Inhibitors Versus Chemoimmunotherapy for Frontline Waldenstrom Macroglobulinemia

BackgroundNo randomized trial has compared Bruton tyrosine kinase inhibitor (BTKi)-based therapy with chemoimmunotherapy (CIT) in frontline Waldenström macroglobulinemia (WM); the RAINBOW trial (NCT04061512) is ongoing.Real-world data are therefore the only current evidence, particularly for older adults, who make up most patients and are underrepresented in trials.